Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""IMMUNOTHERAPY"" wg kryterium: Temat


Starter badań:

Tytuł :
Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Autorzy :
Jin KT; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Du WL; Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.; Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Lan HR; Department of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Liu YY; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Mao CS; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Du JL; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Mou XZ; Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Jul; Vol. 112 (7), pp. 2592-2606. Date of Electronic Publication: 2021 Jun 05.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Disease Models, Animal*
Immunotherapy*
Xenograft Model Antitumor Assays*
Neoplasms/*therapy
Animals ; Antibodies, Monoclonal/therapeutic use ; Cytokines/metabolism ; Drug Development ; Genetic Engineering ; Graft Rejection/immunology ; Graft vs Host Disease/prevention & control ; Humans ; Immunotherapy, Adoptive/methods ; Intercellular Signaling Peptides and Proteins/metabolism ; Killer Cells, Natural/immunology ; Mice ; Mice, SCID ; Neoplasms/immunology ; Precision Medicine ; Translational Medical Research ; Transplantation, Heterologous
Czasopismo naukowe
Tytuł :
Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics.
Autorzy :
Barker-Tejeda TC; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Bazire R; Servicio de Alergia, Instituto de Investigación Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, España.; Servicio de Alergia, Hospital Infantil Universitario Niño Jesús, Fundación para la Investigación Biomédica del Hospital Niño Jesús, Madrid, España.
Obeso D; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Mera-Berriatua L; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Rosace D; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Vazquez-Cortes S; Servicio de Alergia, Hospital Clínico San Carlos, Universidad Complutense, IdISSC, Madrid, España.
Ramos T; Servicio de Alergia, Instituto de Investigación Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, España.
Rico MDP; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Chivato T; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Barbas C; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.
Villaseñor A; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Escribese MM; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Fernández-Rivas M; Servicio de Alergia, Hospital Clínico San Carlos, Universidad Complutense, IdISSC, Madrid, España.
Blanco C; Servicio de Alergia, Instituto de Investigación Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, España.
Barber D; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Pokaż więcej
Źródło :
Allergy [Allergy] 2021 Apr; Vol. 76 (4), pp. 1199-1212. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Rhinitis, Allergic, Seasonal*/diagnosis
Rhinitis, Allergic, Seasonal*/therapy
Sublingual Immunotherapy*
Allergens ; Biomarkers ; Desensitization, Immunologic ; Humans ; Immunotherapy ; Poaceae ; Pollen
Czasopismo naukowe
Tytuł :
Current Immunotherapies for Glioblastoma Multiforme.
Autorzy :
Huang B; Department of Neurosurgery, Beijing Electric Power Hospital, Beijing, China.
Li X; Department of Neurosurgery, Huizhou Third People's Hospital, Guangzhou Medical University, Huizhou, China.
Li Y; Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Guangzhou, China.
Zhang J; Department of Neurosurgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Zong Z; Department of Neurosurgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, China.
Zhang H; Department of Neurosurgery, Huizhou Third People's Hospital, Guangzhou Medical University, Huizhou, China.; Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Guangzhou, China.; Department of Neurosurgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Mar 09; Vol. 11, pp. 603911. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*
Brain Neoplasms/*therapy
Glioblastoma/*therapy
Animals ; Brain Neoplasms/immunology ; Brain Neoplasms/metabolism ; Cancer Vaccines/therapeutic use ; Glioblastoma/immunology ; Glioblastoma/metabolism ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Molecular Targeted Therapy ; Oncolytic Virotherapy ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Autorzy :
Lim CJ; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Nguyen PHD; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Wasser M; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Kumar P; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Lee YH; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Nasir NJM; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.
Chua C; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Lai L; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Hazirah SN; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Loh JJH; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
Khor LY; Duke-NUS Medical School, Singapore, Singapore.; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
Yeong J; Division of Pathology, Singapore General Hospital, Singapore, Singapore.; Institute of Molecular Cell Biology (IMCB), Agency of Science, Technology and Research (ASTAR), Singapore, Singapore.
Lim TKH; Duke-NUS Medical School, Singapore, Singapore.; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
Low AWX; Department of Urology, Singapore General Hospital, Singapore, Singapore.
Albani S; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Chong TW; Duke-NUS Medical School, Singapore, Singapore.; Department of Urology, Singapore General Hospital, Singapore, Singapore.
Chew V; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jan 29; Vol. 11, pp. 615091. Date of Electronic Publication: 2021 Jan 29 (Print Publication: 2020).
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Active*
BCG Vaccine/*therapeutic use
Carcinoma, Transitional Cell/*drug therapy
Lymphocyte Subsets/*immunology
Urinary Bladder Neoplasms/*drug therapy
Carcinoma, Transitional Cell/immunology ; Carcinoma, Transitional Cell/therapy ; Chemotaxis ; Drug Resistance, Neoplasm ; Gene Expression Regulation, Neoplastic/drug effects ; High-Throughput Nucleotide Sequencing ; Humans ; Image Cytometry/instrumentation ; Image Cytometry/methods ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Lymphocyte Activation ; Lymphocyte Count ; Lymphocyte Subsets/drug effects ; Programmed Cell Death 1 Receptor/analysis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Receptors, Antigen, T-Cell/analysis ; Single-Cell Analysis ; T-Lymphocyte Subsets/chemistry ; T-Lymphocyte Subsets/immunology ; Time Factors ; Transcriptome ; Tumor Escape ; Urinary Bladder Neoplasms/immunology ; Urinary Bladder Neoplasms/therapy
Czasopismo naukowe
Tytuł :
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15 February 2019, Doha, Qatar.
Autorzy :
Guerrouahen B; Research Department, Sidra Medicine, Doha, Qatar.
Elnaggar M; Research Department, Sidra Medicine, Doha, Qatar.
Al-Mohannadi A; Research Department, Sidra Medicine, Doha, Qatar.
Kizhakayil D; Research Department, Sidra Medicine, Doha, Qatar.
Bonini C; Experimental Hematology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, Italy.
Benjamin R; Division of Cancer Studies, King's College Hospital, London, United Kingdom.
Brentjens R; Cellular Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Buchholz CJ; Research Unit for Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.
Casorati G; Experimental Immunology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, Italy.
Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, United States.
Martin F; Pfizer/University of Granada/Andalusian Regional Government, Genomic Medicine Department, Granada, Spain.
Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boson, MA, United States.
Turtle C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Veys P; Bone Marrow Transplant Unit, Great Ormond Street (GOS) Hospital, and University College London GOS Institute of Child Health, London, United Kingdom.
van der Vliet HJ; Hans van Der Vliet, Department of Medical Oncology, Amsterdam UMC, VU University and Cancer Center, Amsterdam, Netherlands.; Lava Therapeutics, Utrecht, Netherlands.
Maccalli C; Research Department, Sidra Medicine, Doha, Qatar.
Pokaż więcej
Corporate Authors :
EICCI Faculty Group
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jan 14; Vol. 11, pp. 589381. Date of Electronic Publication: 2021 Jan 14 (Print Publication: 2020).
Typ publikacji :
Congress; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*
Neoplasms/*therapy
Animals ; Genetic Engineering ; Humans ; Immunotherapy, Adoptive ; Qatar ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes/immunology
Raport
Tytuł :
NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Autorzy :
Sanchez CE; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Dowlati EP; Department of Neurosurgery, Georgetown University Hospital, Washington, DC.
Geiger AE; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Chaudhry K; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Tovar MA; School of Medicine and Health Sciences, George Washington University, Washington, DC.
Bollard CM; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC; School of Medicine and Health Sciences, George Washington University, Washington, DC.
Cruz CRY; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC; School of Medicine and Health Sciences, George Washington University, Washington, DC. Electronic address: .
Pokaż więcej
Źródło :
Transplantation and cellular therapy [Transplant Cell Ther] 2021 Jan; Vol. 27 (1), pp. 21-35. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy, Adoptive*
Neoplasms*/therapy
Humans ; Immunotherapy ; Killer Cells, Natural ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
Autorzy :
Li W; Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Peng A; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Wu H; Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Quan Y; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.; Faculty of Health Sciences, University of Macau, Macau, China.
Li Y; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Lu L; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Cui M; Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Dec 21; Vol. 11, pp. 601497. Date of Electronic Publication: 2020 Dec 21 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Genetic Therapy*/adverse effects
Immunotherapy*/adverse effects
Photothermal Therapy*/adverse effects
Theranostic Nanomedicine*
Antineoplastic Agents/*therapeutic use
Nanoparticles/*therapeutic use
Neoplasms/*therapy
Animals ; Antineoplastic Agents/adverse effects ; Cytotoxicity, Immunologic ; Drug Carriers ; Gene Expression Regulation, Neoplastic ; Humans ; Immunotherapy, Adoptive ; Nanoparticles/adverse effects ; Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/metabolism ; Signal Transduction ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Improving safety of cancer immunotherapy via delivery technology.
Autorzy :
Hu D; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Zhang W; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Tang J; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China. Electronic address: .
Zhou Z; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Liu X; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Shen Y; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Pokaż więcej
Źródło :
Biomaterials [Biomaterials] 2021 Jan; Vol. 265, pp. 120407. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*
Neoplasms*/therapy
Animals ; Autoimmunity ; Immunotherapy, Adoptive ; Technology ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Microbial short-chain fatty acids modulate CD8 T cell responses and improve adoptive immunotherapy for cancer.
Autorzy :
Luu M; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Riester Z; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Baldrich A; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Reichardt N; 4DPharma Research Ltd., Aberdeen, United Kingdom.
Yuille S; 4DPharma Research Ltd., Aberdeen, United Kingdom.
Busetti A; 4DPharma Research Ltd., Aberdeen, United Kingdom.
Klein M; Institute for Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Wempe A; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Leister H; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Raifer H; Flow Cytometry Core Facility, Philipps University Marburg, Marburg, Germany.
Picard F; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Muhammad K; Department of Biology, United Arab Emirates University, Al Ain, United Arab Emirates.
Ohl K; Department of Pediatrics, RWTH Aachen University, Aachen, Germany.
Romero R; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Fischer F; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Bauer CA; Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, University Hospital Marburg, UKGM, Philipps University Marburg, Marburg, Germany.
Huber M; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Gress TM; Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, University Hospital Marburg, UKGM, Philipps University Marburg, Marburg, Germany.
Lauth M; Institute of Molecular Biology and Tumor Research, Center for Tumor- and Immunobiology, Philipps-University Marburg, Marburg, Germany.
Danhof S; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Bopp T; Institute for Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Nerreter T; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Mulder IE; 4DPharma Research Ltd., Aberdeen, United Kingdom.
Steinhoff U; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
Hudecek M; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany. .
Visekruna A; Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jul 01; Vol. 12 (1), pp. 4077. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CD8-Positive T-Lymphocytes/*metabolism
Fatty Acids, Volatile/*metabolism
Immunologic Factors/*metabolism
Immunotherapy, Adoptive/*methods
Microbiota/*physiology
Neoplasms/*immunology
T-Lymphocytes, Cytotoxic/*immunology
Animals ; Butyrates/metabolism ; Cell Line, Tumor ; Cytokines/metabolism ; Female ; Immunotherapy ; Interferon-gamma ; Interleukin-2 Receptor alpha Subunit ; Megasphaera ; Melanoma/metabolism ; Mice ; Mice, Inbred C57BL ; Peptide Fragments ; Receptor Tyrosine Kinase-like Orphan Receptors ; Receptors, G-Protein-Coupled/genetics ; Tumor Necrosis Factor-alpha
SCR Organism :
Megasphaera massiliensis
Czasopismo naukowe
Tytuł :
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Autorzy :
Major A; Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Collins J; Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Craney C; Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Heitman AK; Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Bauer E; Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Zerante E; Section of Hematology/Oncology at the University of Chicago, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Stock W; The David and Etta Jonas Center for Cellular Therapy at the University of Chicago, Chicago, IL, USA.
Bishop MR; The David and Etta Jonas Center for Cellular Therapy at the University of Chicago, Chicago, IL, USA.
Jasielec J; The David and Etta Jonas Center for Cellular Therapy at the University of Chicago, Chicago, IL, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Jul; Vol. 62 (7), pp. 1765-1769. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Case Reports; Letter; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Lymphohistiocytosis, Hemophagocytic*/diagnosis
Lymphohistiocytosis, Hemophagocytic*/etiology
Lymphohistiocytosis, Hemophagocytic*/therapy
Receptors, Chimeric Antigen*/genetics
Immunotherapy, Adoptive/*adverse effects
Cytokines/antagonists & inhibitors ; Female ; Humans ; Immunotherapy ; T-Lymphocytes ; Young Adult
Recenzja
Tytuł :
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Autorzy :
Taha T; Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Reiss A; Division of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, Israel.
Amit A; Division of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, Israel.; Technion, Israel Institute of Technology, Haifa, Israel.
Perets R; Division of Oncology, Rambam Health Care Campus, Haifa, Israel. .; Technion, Israel Institute of Technology, Haifa, Israel. .; Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa, Israel. .
Pokaż więcej
Źródło :
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2020 Dec; Vol. 34 (6), pp. 749-762.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Genital Neoplasms, Female*/drug therapy
Immunotherapy*
Biomarkers, Tumor ; Female ; Humans ; Immunotherapy, Adoptive ; Microsatellite Instability ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Colorectal Cancer Immunotherapy: Options and Strategies.
Autorzy :
Johdi NA; UKM Medical Molecular Biology Institute (UMBI), National University of Malaysia, Bangi, Malaysia.
Sukor NF; UKM Medical Molecular Biology Institute (UMBI), National University of Malaysia, Bangi, Malaysia.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Sep 18; Vol. 11, pp. 1624. Date of Electronic Publication: 2020 Sep 18 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Disease Management*
Immunotherapy*/adverse effects
Immunotherapy*/methods
Colorectal Neoplasms/*immunology
Colorectal Neoplasms/*therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; Cancer Vaccines ; Colorectal Neoplasms/pathology ; Combined Modality Therapy ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Molecular Targeted Therapy/adverse effects ; Molecular Targeted Therapy/methods
Czasopismo naukowe
Tytuł :
Frontiers in cancer immunotherapy-a symposium report.
Autorzy :
Cable J; PhD Science Writer, New York, New York.
Greenbaum B; Computational Oncology, Program for Computational Immuno-Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer, New York, New York.
Pe'er D; Program for Computational and Systems Biology, Sloan Kettering Institute and Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
Bollard CM; Center for Cancer and Immunology Research, Children's National Hospital, The George Washington University, Washington, District of Columbia.
Bruni S; Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.
Griffin ME; Laboratory of Chemical Biology and Microbial Pathogenesis, The Rockefeller University New York, New York, New York.
Allison JP; Immunotherapy Platform and Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Subudhi SK; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Mardis ER; The Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio.
Brentjens R; Department of Medicine and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.
Sosman JA; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Cemerski S; Cue Biopharma, Cambridge, Massachusetts.
Zavitsanou AM; Department of Pathology, New York University School of Medicine, New York, New York.
Proia T; AstraZeneca, Waltham, Massachusetts.
Egeblad M; Cold Spring Harbor Laboratory, Cancer Center, New York, New York.
Nolan G; Baxter Laboratory in Stem Cell Biology and Department of Microbiology and Immunology, Stanford University, Stanford, California.; Parker Institute for Cancer Immunotherapy, San Francisco, California.
Goswami S; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Spranger S; Koch Institute for Integrative Cancer Research and Biology Department, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, California.; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Stanford University School of Medicine, Stanford, California.
Pokaż więcej
Źródło :
Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2021 Apr; Vol. 1489 (1), pp. 30-47. Date of Electronic Publication: 2020 Nov 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive*
Immunotherapy/*trends
Neoplasm Recurrence, Local/*therapy
Neoplasms/*therapy
Biomarkers, Tumor/genetics ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Combined Modality Therapy ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Neoplasm Recurrence, Local/immunology ; Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/pathology ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
Autorzy :
Genoud V; Department of Oncology, University Hospital of Geneva, 1205 Geneva, Switzerland.; Center for Translational Research in Onco-Haematology, University of Geneva, 1205 Geneva, Switzerland.
Migliorini D; Department of Oncology, University Hospital of Geneva, 1205 Geneva, Switzerland.; Center for Translational Research in Onco-Haematology, University of Geneva, 1205 Geneva, Switzerland.; Brain Tumor and Immune Cell Engineering Laboratory, 1005 Lausanne, Switzerland.; Swiss Cancer Center Léman, 1205 Geneva, Switzerland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 28; Vol. 22 (7). Date of Electronic Publication: 2021 Mar 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Brain Neoplasms/*immunology
Brain Neoplasms/*therapy
Glioblastoma/*immunology
Glioblastoma/*therapy
Immunotherapy/*methods
Cancer Vaccines/therapeutic use ; Central Nervous System/pathology ; Clinical Trials as Topic ; Humans ; Immune System ; Immunotherapy, Adoptive/methods ; Immunotherapy, Adoptive/trends ; Medical Oncology/methods ; Medical Oncology/trends ; Neoplasm Metastasis ; Oncolytic Viruses
Czasopismo naukowe
Tytuł :
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Autorzy :
Yang C; Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xia BR; Department of Gynecology Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Zhang ZC; Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Zhang YJ; Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Lou G; Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jin WL; Department of Instrument Science and Engineering, Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai, China.; National Center for Translational Medicine, Collaborative Innovational Center for System Biology, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Oct 06; Vol. 11, pp. 577869. Date of Electronic Publication: 2020 Oct 06 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*/adverse effects
Neoadjuvant Therapy*/adverse effects
Ovarian Neoplasms/*therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cancer Vaccines/therapeutic use ; Chemotherapy, Adjuvant ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Oncolytic Virotherapy ; Ovarian Neoplasms/immunology ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
State-of-Art of Cellular Therapy for Acute Leukemia.
Autorzy :
Lee JB; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
Vasic D; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Kang H; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Fang KK; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Zhang L; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.; Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Apr 27; Vol. 22 (9). Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive/*methods
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Acute Disease ; Cell- and Tissue-Based Therapy ; Humans ; Immunotherapy ; Immunotherapy, Adoptive/trends ; Killer Cells, Natural/immunology ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/therapy ; Leukemia, T-Cell/metabolism ; Leukemia, T-Cell/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Receptors, Chimeric Antigen/metabolism ; T-Lymphocytes/immunology
Czasopismo naukowe
Tytuł :
The emerging role of immunotherapy for the treatment of sarcoma.
Autorzy :
Klemen ND; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kelly CM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Bartlett EK; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Pokaż więcej
Źródło :
Journal of surgical oncology [J Surg Oncol] 2021 Mar; Vol. 123 (3), pp. 730-738. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy/*methods
Sarcoma/*therapy
Animals ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase III as Topic ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive/methods ; Interleukin-2/therapeutic use ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.
Autorzy :
Innao V; Division of Hematology, Department of Human Pathology in Adulthood and Childhood, University of Messina, 98122 Messina, Italy.
Allegra AG; Radiation Oncology Unit, Department of Biomedical, Experimental, and Clinical Sciences 'Mario Serio', Azienda Ospedaliero-Universitaria Careggi, University of Florence, 50100 Florence, Italy.
Musolino C; Division of Hematology, Department of Human Pathology in Adulthood and Childhood, University of Messina, 98122 Messina, Italy.
Allegra A; Division of Hematology, Department of Human Pathology in Adulthood and Childhood, University of Messina, 98122 Messina, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Nov 24; Vol. 21 (23). Date of Electronic Publication: 2020 Nov 24.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy*
Gastrointestinal Microbiome/*drug effects
Immune Checkpoint Inhibitors/*therapeutic use
Neoplasms/*therapy
B7-H1 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/antagonists & inhibitors ; Humans ; Immunotherapy, Adoptive ; Neoplasms/immunology ; Neoplasms/microbiology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Autorzy :
Waldman AD; Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Clinical Genomics Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Fritz JM; Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Clinical Genomics Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lenardo MJ; Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. .; Clinical Genomics Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. .
Pokaż więcej
Źródło :
Nature reviews. Immunology [Nat Rev Immunol] 2020 Nov; Vol. 20 (11), pp. 651-668. Date of Electronic Publication: 2020 May 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*/trends
Neoplasms/*therapy
T-Lymphocytes/*immunology
Animals ; Cancer Vaccines/therapeutic use ; Clinical Trials as Topic ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy, Adoptive
Czasopismo naukowe
Tytuł :
Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
Autorzy :
Li L; Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) Bethesda, Maryland 20892, United States.
Yang Z; Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) Bethesda, Maryland 20892, United States.
Chen X; Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) Bethesda, Maryland 20892, United States.
Pokaż więcej
Źródło :
Accounts of chemical research [Acc Chem Res] 2020 Oct 20; Vol. 53 (10), pp. 2044-2054. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy*
Neoplasms/*therapy
Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunogenic Cell Death ; Immunotherapy, Adoptive ; Indoleamine-Pyrrole 2,3,-Dioxygenase/antagonists & inhibitors ; Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism ; Membrane Proteins/agonists ; Membrane Proteins/metabolism ; Nanoparticles/chemistry ; Neoplasms/drug therapy ; Neoplasms/pathology ; Phototherapy ; Reactive Oxygen Species/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies